Conduit Pharmaceuticals
About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Employees: 7
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
667% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 3
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
25% more funds holding
Funds holding: 36 [Q3] → 45 (+9) [Q4]
24% more capital invested
Capital invested by funds: $482K [Q3] → $599K (+$117K) [Q4]
3.05% more ownership
Funds ownership: 4.24% [Q3] → 7.29% (+3.05%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CDT.
Financial journalist opinion
Based on 3 articles about CDT published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq”) Hearing Panel (the "Panel”) and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price”), Market Value of Publicly Held Shares ("MVPHS”) and Market Value of Listed Securities ("MVLS”) rules, respectively.
Neutral
GlobeNewsWire
3 weeks ago
Conduit Progresses Phase II of its AI Initiative with Sarborg
Collaboration reinforces Conduit's commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit's Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited.
Neutral
GlobeNewsWire
4 weeks ago
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN).
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the repayment of its $600,000 promissory note (the “Note”) to Nirland Limited (“Nirland”) and provided an update on the conversion of its Senior Secured Promissory Note (the “Senior Note”) with Nirland.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic. NAPLES, Fla.
Neutral
GlobeNewsWire
1 month ago
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-100 reverse stock split of the Company's common stock.
Neutral
GlobeNewsWire
3 months ago
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio.
Neutral
GlobeNewsWire
3 months ago
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company's lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders.
Neutral
GlobeNewsWire
3 months ago
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla.
Neutral
GlobeNewsWire
4 months ago
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
SAN DIEGO and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (“Conduit” or the “Company”), today announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a broad spectrum of autoimmune disorders.
Charts implemented using Lightweight Charts™